References
- Wells SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. the american thyroid association guidelines task force on medullary thyroid carcinoma. Thyroid 2015
- Bihan H, Baudin E, Meas T, et al. Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma. Head Neck 2012;34(4):493-8
- Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999;90(1):1-5
- Nakao KT, Usui T, Ikeda M, et al. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis. Head Neck 2013;35(12):E363-8
- Bartsch DK, Hasse C, Schug C, et al. A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 2000;108(2):128-32
- Valente FO, Dias da Silva MR, Camacho CP, et al. Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families. J Endocrinol Invest 2013;36(11):975-81
- Machens A, Spitschak A, Lorenz K, et al. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation? Clin Endocrinol (Oxf) 2011;75(6):801-5
- Colombo-Benkmann M, Li Z, Riemann B, et al. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 2008;158(6):811-16